Asia Deal Watch: Otsuka Gets Japanese Rights To Perception’s Mood Disorder Candidate
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
You may also be interested in...
Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors
Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.
Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.
Samsung Bioepis Partners With Yuhan On Korean Adalimumab
Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.